Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-Risk Neuroblastoma: A Groupwide Historically Controlled Phase III Study

S
Sandeep Batra, MD

Primary Investigator

Overview

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.

Description

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    neuroblastoma
  • Age: - 1 Years
  • Gender: All

Inclusion Criteria
12 months of age at diagnosis with INRG stage L1 or stage M neuroblastoma or nrollment on ANBLOOB1 is required for all newly diagnosed patients
Must have newly diagnosed v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma verified by histology
Exclusion Criteria
Patients with MYCN amplified tumors
Additional Information:
Participants will not be paid for their participation.

Updated on 05 Jul 2023. Study ID: 1410350695 (PHO-COG-FALLON-ANBL1232)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center